Your email has been successfully added to our mailing list.

×
0.0116959064327485 0.0116959064327485 0.0116959064327485 0.0116959064327485 0.0116959064327485 -0.0248538011695906 -0.0248538011695906 -0.0248538011695906
Stock impact report

AGC Biologics to Manufacture AAVantgarde's Dual-Vector Gene Therapies for Inherited Retinal Disorders [Yahoo! Finance]

AGC INC UNSP/ADR (ASGLY) 
Company Research Source: Yahoo! Finance
MILAN, November 21, 2025 BUSINESS WIRE )--On the heels of AAVantgarde closing a Series B financing round , AGC Biologics announced a new manufacturing agreement with the biotechnology company, marking AGC Biologics' latest advancement in the adeno-associated virus market. Under this agreement, AGC Biologics will provide Good Manufacturing Practice manufacturing for AAVantgarde's two novel candidates designed to address progressive and irreversible vision loss where there are currently no approved therapies: Show less Read more
Impact Snapshot
Event Time:
ASGLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ASGLY alerts
Opt-in for
ASGLY alerts

from News Quantified
Opt-in for
ASGLY alerts

from News Quantified